Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Sangamo BioSciences (SGMO) PT Raised to $6 at WedbushMay 16, 2017 8:45 AM Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene TherapyMay 16, 2017 7:30 AM